posted                      

Guidant Corporation, Jacobson Resonance Enterprises, Inc. and The Oklahoma Foundation for Cardiovascular Research Co-Sponsor and Fund Phase II Clinical Trial
1/22/2004 9:05:35 AM
BOYNTON BEACH, FL, Jan. 22, 2004 (MARKET WIRE via COMTEX) -- Jacobson Resonance Enterprises, Inc. (JRSE) , a biotechnology company, announces the initiation of a Phase II clinical trial. The trial will be co-sponsored and funded by Guidant Corporation, JRSE and the Oklahoma Foundation for Cardiovascular Research. The study is targeted to begin in Q3/Q4, 2004. The research will involve patients with chronic stable angina refractory to medical, surgical and other interventional cardiac procedures. These patients will engage in an exercise tolerance test before and after exposure to the Jacobson magnetic field. The exact mechanism of the Jacobson field has not been elucidated; however, it is hypothesized that it is altering the cell membrane by effecting ionic channels. This has been shown in preclinical testing. Although the exact mechanism is not known, quantifiable and reproducible measurements of the Jacobson field have been completed. The hypothesis of this study is that exposure to the Jacobson magnetic field will increase time on the treadmill and increase time to angina.
The trial will be completed through the Oklahoma Foundation for Cardiovascular Research located in Oklahoma City. The principal investigator will be Dr. Michael Scherlag, MD, an interventional cardiologist whose experience in administering clinical trials dates from his Duke University residency.
Preclinical testing has shown the ability of the magnetic field to decrease nerve traffic from a painful stimulus. Other studies have shown an effect of the magnetic field to increase parasympathetic tone evidenced by a decrease in heart rate. The current trial will capitalize on these two effects. Decreased heart rate and decreased painful nerve traffic should combine to lessen angina and increase time on an exercise tolerance test.
Patients with refractory angina have few options at this time. Current therapies available include Enhanced External Counterpulsation, calcium channel blockers and beta-blockers among others. These treatments have side effects and are not tolerated in all patients. It is hoped that the non-invasive approach using Jacobson Resonance therapy will be well tolerated and effective.
Based on preclinical testing, other trials are currently being designed to evaluate the effectiveness of the magnetic field on a common cardiac arrhythmia, atrial fibrillation. Atrial fibrillation will occur in close to 10% of persons over the age of 70. The preclinical data will be released at the American College of Cardiology in March at New Orleans.
JRSE is an emerging worldwide leader in magnetic resonance technology, whose main focus is the eradication of human suffering. The Company's technology base has the potential for multiple industry applications including the fields of medicine, spa and leisure arena, food and beverage, pharmaceuticals, energy and the environment.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The matters covered by such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of the Company to differ materially from those contemplated or implied by such forward-looking statements. Included in these risks and other factors are funding availability, competition from better-financed companies and required regulatory clearances.
For further information
Contact:
Anthony P. Fusco, Jr.
(561) 752.4141

IP: Logged |